Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, multi-centre, phase III, subject initiated safety study of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] in treatment of recurrent herpes simplex labialis in adolescents,

Next Previous
X
Search
Trial Profile

An open label, multi-centre, phase III, subject initiated safety study of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] in treatment of recurrent herpes simplex labialis in adolescents,

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aciclovir/hydrocortisone (Primary)
  • Indications Herpes labialis
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Oct 2010 Results presented as a poster at the American Osteopathic Association's (AOA) 115th Osteopathic Medical Conference and Exposition.
    • 19 Mar 2008 Results from the phase III program reported in a Medivir media release.
    • 13 Feb 2008 Results from the Lipsovir phase III program are expected in late March or early April 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top